Nov 19 2024 @ 7:00 PM - 1) HPV-positive Oropharyngeal Cancer and 2) Targeting Inflammation in Treated HIV, version 3.0
HPV-positive Oropharyngeal Cancer in People With or At-risk for HIV
Anil K. Chaturvedi, Ph.D. and Scott A. Roof, MD MS
Anil K. Chaturvedi, Ph.D.
Senior Investigator, Clinical Epidemiology Unit, Clinical Genetics Branch
Senior Advisor for Faculty Development
Division of Cancer Epidemiology and Genetics
National Cancer Institute, National Institutes of Health
Rockville, MD
Scott A. Roof, MD MS
Assistant Professor
Director of Clinical Research
Division of Head and Neck Oncology and Microvascular Surgery
Department of Otolaryngology - Head and Neck Surgery
Icahn School of Medicine at Mount Sinai
Targeting Inflammation in Treated HIV, version 3.0
Peter W. Hunt, MD
Professor of Medicine, Division of Experimental Medicine, UCSF
Co-Director of Basic/Translational Sciences, Center for AIDS Research
San Francisco, CA
Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine at UCSF and Co-Director of the UCSF-Bay Area Center for AIDS Research for Basic and Translational Science. His primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand the causes and consequences of persistent immune activation and its impact on aging-associated multi-morbidity and mortality in treated HIV infection, as well as its impact on HIV persistence. He also conducts clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group (ACTG). Dr. Hunt led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In July, 2016, he also started a laboratory to better characterize the immune defects that drive morbidity and mortality in treated HIV, with a specific focus on the role of CMV co-infection as an important mediator. He leads a large clinical trial of the anti-CMV drug letermovir in the ACTG, exploring its impact not just on systemic inflammation, but also on cardiometabolic and neurocognitive outcomes. He has also recently extended his CMV work to address its impact on COVID-19 pathogenesis.